ABAnke Baranowsky

Anke Baranowsky

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anke Baranowsky has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Wnt1 controls subchondral bone remodeling and osteoarthritis progression

    by Weixin Xie, Antonia Donat, Shan Jiang, Haoyan Pan, Ruben Augustin, Till Schoberwalter, Chiara Gerriets, Jan Sevecke, Cordula Erdmann, Saskia Schröder, et al.

    Despite mounting evidence emphasizing the role of abnormal subchondral bone remodeling in the progression of osteoarthritis (OA), clinical translation has produced disappointing results. Here, we demonstrate an increased expression of Wnt1, a key Wnt ligand with potent osteoanabolic effects, during OA progression in human and murine subchondral bone. Temporarily overexpressing Wnt1 in osteoblasts in the early phase after anterior cruciate ligament transection (ACLT)-induced OA has no effect on cartilage degeneration; however, it contributes to increased subchondral bone mass and alleviates subchondral bone loss. In contrast, late-phase induction of Wnt1 in osteoblasts exacerbates OA severity by inducing aberrant subchondral bone sclerosis, where inflammation-induced secreted frizzled-related protein 2 (Sfrp2) in the subchondral bone potentiates the harmful effects of Wnt1. Moreover, mice with a global inactivating Wnt1 G177C mutation, which clinically causes osteogenesis imperfecta type XV, display low subchondral bone mass, are resistant to ACLT-induced subchondral bone loss and exhibit attenuated OA progression. Taken together, these findings identify a pathophysiological role for Wnt1 in subchondral bone remodeling and OA progression that could represent a promising therapeutic target.

  • Sustained neutrophil extracellular traps cause fracture nonunion

    by Weixin Xie, Lilly-Charlotte Albertsen, Gesine Eis-Janzyk, Charlotte Kühlwein, Shan Jiang, Carsten Schlickewei, Holger Kleinertz, Ruben Augustin, Jan Sevecke, Saskia Schröder, et al.

    Fracture healing is an evolutionarily conserved process that depends on the complex interplay of osteogenic, angiogenic, and inflammatory responses. Impaired bone healing is observed in up to 10 to 15% of patients with fractures and can lead to nonunion, which is the absence of bone healing. Here, we explore a role of neutrophil extracellular traps (NETs) in fracture healing and their association with nonunion. In both mice and humans, skeletal injury triggers rapid but transient NET formation at the fracture site. The combined genetic deletion of enzymes essential for NET clearance, DNase1 and DNase1-like-3 , initially favors callus mineralization in the early healing phase. However, sustained NET elevation subsequently leads to impaired bone regeneration and fracture nonunion over the course of healing. Conversely, additional deletion of the NET-generating enzyme Pad4 improves bone regeneration and lowers nonunion rates. Mechanistically, NETs up-regulate cGas-Sting signaling, thereby collapsing the formation of type-H vessels, which couple osteogenesis to angiogenesis in the fracture callus. Pharmacological inhibition of cGas-Sting restored type-H vessels, enhanced bone healing, and prevented nonunion in DNase -deficient but not Pad4 -deficient mice. In patients, serum NET markers declined during normal healing but were elevated in nonunion, correlating with excessive NET and STING accumulation in the callus. Therapeutically, the inhibition of NET formation with the Pad4 inhibitor GSK484 or the promotion of NET clearance with dornase alfa (recombinant DNase1) accelerated bone repair and prevented nonunion in preclinical models. These findings identify sustained NETs as a disruptor of fracture healing and a potential target for enhancing bone regeneration.


  • Extracellular traps from myeloid cells as therapeutic targets in traumatic heterotopic ossification

    by Shan Jiang, Gesine Eis-Janzyk, Ruben Augustin, Holger Kleinertz, Saskia Schröder, Jan Sevecke, Weixin Xie, Haoyan Pan, Isabell Behrens, Samira Weisselberg, et al.

    After musculoskeletal injury, a considerable proportion of patients develop heterotopic ossification (HO), the formation of bone at ectopic sites. Traumatic HO is a disabling condition, potentially resulting in loss of joint function and compression of neurovascular structures. Available treatment options are often unsuccessful, frequently necessitating surgical resection of HO lesions with a high risk of recurrence. Given that myeloid cells, including neutrophils and macrophages, are among the first cell types to infiltrate injured tissue, the present study explored the relationship of extracellular traps (ETs) with HO formation in humans and mice. Human HO sample analysis revealed the presence of different stages of ETosis, which are clinically associated with increased ET concentrations in the blood. Experimentally, genetic impairment of ET resolution through combined DNase1 and DNase1l3 deficiency led to increased traumatic HO in mice, whereas HO was strongly attenuated by additional deletion of the ET generator Padi4 . Neutrophil depletion impaired local ET formation, reduced HO formation, and blunted genotype-specific differences in HO outcome. In osteogenic precursors, ETs promoted matrix mineralization, and inhibition of ETosis or degradation of cell-free DNA, a major ET component, resulted in reduced osteogenesis. Pharmacological facilitation of ET clearance by dornase alfa, a US Food and Drug Administration–approved recombinant DNase1, or inhibition of ETs by the PADI4 inhibitor GSK484, resulted in inhibition of traumatic HO formation in mice without adversely affecting systemic bone remodeling. Together, our clinical and experimental findings demonstrate that traumatic HO is mediated by targetable neutrophil-dependent mechanisms, with altered ET formation contributing to these effects.


  • Open Access

    The calcitonin receptor controls osteophyte formation, but not cartilage degeneration and subchondral bone loss in experimental osteoarthritis

    by Shan Jiang, Weixin Xie, Tobias M. Ballhause, Jan Sevecke, Ruben Augustin, Tim Rolvien, Tazio Maleitzke, Anke Baranowsky, Johannes Keller

    Aims: Salmon calcitonin (CT) has been shown to have antiresorptive and chondroprotective effects, and several clinical trials have reported beneficial effects of salmon CT treatment in patients with knee osteoarthritis (OA). The objective of the present study is to investigate the role of endogenous CT-mediated signalling in OA. Methods: Calcitonin receptor (CTR)-deficient mice and wild-type (WT) littermate controls were subjected to experimental post-traumatic OA (ptOA) by anterior cruciate ligament transection (ACLT). Radiological and histomorphometric outcome measurements in WT and CTR -deficient mice with ACLT were performed at early (4 weeks) and late (8 weeks) stages after ptOA induction. Expression of CTR on messenger RNA (mRNA) and protein level in sham and ACLT knees of WT mice were measured by gene expression analysis and immunofluorescence, respectively. Results: In WT mice, Calcr mRNA was progressively induced in ptOA knees, and CTR protein was abundantly expressed in articular cartilage and subchondral bone (SB) in diseased joints. CTR -/- mice displayed decreased osteophyte formation compared to WT mice, while cartilage deterioration, pathological SB alterations, and synovial inflammation were not affected by CTR deficiency. In line with this, bone resorption, cartilage, and inflammatory markers were unaltered between WT and CTR -deficient mice, while bone formation parameters were increased only in WT ptOA knees on gene expression level four weeks after surgery. Conclusion: Although CTR is highly expressed in articular cartilage and SB and promotes osteophyte formation, endogenous CTR signalling does not affect cartilage degeneration and SB pathologies in murine ptOA. Cite this article: Bone Joint Res 2026;15(2):190–203.


  • Open Access

    Spatio-temporal characterization of compositional and cellular properties in the murine fracture callus

    by Tobias M. Ballhause, Ana Ocokoljic, Jan Sevecke, Alexander Simon, Anke Baranowsky, Assil-Ramin Alimy, Frank Timo Beil, Karl-Heinz Frosch, Johannes Keller, Tim Rolvien


  • Increased β 2 -adrenergic signaling promotes fracture healing through callus neovascularization in mice

    by Denise Jahn, Paul Richard Knapstein, Ellen Otto, Paul Köhli, Jan Sevecke, Frank Graef, Christine Graffmann, Melanie Fuchs, Shan Jiang, Mayla Rickert, et al.

    Traumatic brain injury (TBI) leads to skeletal changes, including bone loss in the unfractured skeleton, and paradoxically accelerates healing of bone fractures; however, the mechanisms remain unclear. TBI is associated with a hyperadrenergic state characterized by increased norepinephrine release. Here, we identified the β 2 -adrenergic receptor (ADRB2) as a mediator of skeletal changes in response to increased norepinephrine. In a murine model of femoral osteotomy combined with cortical impact brain injury, TBI was associated with ADRB2-dependent enhanced fracture healing compared with osteotomy alone. In the unfractured 12-week-old mouse skeleton, ADRB2 was required for TBI-induced decrease in bone formation and increased bone resorption. Adult 30-week-old mice had higher bone concentrations of norepinephrine, and ADRB2 expression was associated with decreased bone volume in the unfractured skeleton and better fracture healing in the injured skeleton. Norepinephrine stimulated expression of vascular endothelial growth factor A and calcitonin gene–related peptide-α (αCGRP) in periosteal cells through ADRB2, promoting formation of osteogenic type-H vessels in the fracture callus. Both ADRB2 and αCGRP were required for the beneficial effect of TBI on bone repair. Adult mice deficient in ADRB2 without TBI developed fracture nonunion despite high bone formation in uninjured bone. Blocking ADRB2 with propranolol impaired fracture healing in mice, whereas the ADRB2 agonist formoterol promoted fracture healing by regulating callus neovascularization. A retrospective cohort analysis of 72 patients with long bone fractures indicated improved callus formation in 36 patients treated with intravenous norepinephrine. These findings suggest that ADRB2 is a potential therapeutic target for promoting bone healing.


  • Open Access

    The gap junction protein Panx3 is essential for bone regeneration+

    by Shan Jiang, Tobias Ballhause, Anke Baranowsky, Saskia Schröder, Thorsten Schinke, Johannes Keller

  • Open Access

    The chemokine Cxcl9 is a crucial regulator of bone healing

    by Shan Jiang, Tobias Ballhause, Paul-Richard Knapstein, Antonia Donat, Anke Baranowsky, Johannes Keller

  • Open Access

    RAI2 as a novel suppressor of cancer cell homing and survival in the bone microenvironment

    by Thais Pereira-Veiga, Stefan Werner, Desiree Loreth, Michael Horn, Anke Baranowsky, Hanna Taipaleenmäki, Laura Brylka, Jolanthe Kropidlowski, Thorsten Schinke, Klaus Pantel, et al.

  • Open Access

    Cold exposure has a negative impact on bone mass in vivo

    by Friederike Behler-Janbeck, Anke Baranowsky, Julian Stürznickel, Thorsten Schinke, Joerg Heeren